

CONTENTS

Chapter 1	General Introduction	9
Chapter 2	HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review	31
Chapter 3	Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V	57
Chapter 4	Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines	75
Chapter 5	Cellular resistance to HIV protease inhibitor lopinavir in a human T cell line (CEM) is associated with ABCG1 downregulation and decreased apoptosis capacity	93
Chapter 6	The lopinavir/ritonavir-associated rise in lipids is not related to the lopinavir or ritonavir plasma concentration	115
Chapter 7	General discussion Where we stand with HIV protease inhibitors: a SWOT analysis	131
Chapter 8	Summary	151
Addendum	Dutch summary - Nederlandse samenvatting	158
	Acknowledgements - Dankwoord	162
	Curriculum vitae	165
	List of publications	166